Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Business Wire•13/10/2026•07:00 ET
0
Key Highlights
- ➤Enanta will present Phase 2 zelicapavir data for high-risk adults at IDWeek 2026
- ➤Zelicapavir is an oral, once-daily N-protein inhibitor in development for RSV
- ➤Poster reports decreased time to complete symptom resolution, hospitalization and viral load
- ➤Presentation scheduled October 22, 2026, with presenter Christopher E. Harris, M.D.
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center in Washington, DC.
Get started
Create a free account to read the full story.